Examining miRNA Signatures in Glioma for Clinical Use
Deciphering the Functional Role of a Three-miRNA Signature in Glioma: From Molecular Mechanisms to Potential Clinical Application
This study is testing how certain tiny molecules in the body affect glioma tumors and their response to treatments like radiation and a common chemotherapy drug, to help improve care for glioma patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT06883214 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of three specific miRNAs on glioma biology, focusing on their roles in cell viability, proliferation, migration, and invasion. Researchers will utilize gain/loss of function strategies with primary glioma cells from patients with different IDH statuses. The study aims to understand how these miRNAs affect treatment responses, particularly to radiotherapy and temozolomide, in glioma patients. The research will be based on well-characterized glioma cell lines and surgical tissue samples.
Who should consider this trial
Good fit: Ideal candidates include patients with a histological diagnosis of glioma who have available surgical tissue and no other primary tumors.
Not a fit: Patients with non-glial tumors or those with metastatic disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for glioma patients, enhancing their response to existing therapies.
How similar studies have performed: Other studies have shown promise in utilizing miRNA signatures for treatment response in various tumors, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * histological diagnosis of glioma; * no concomitant primary tumor; * no metastatic disease; * availability of surgical material/tissue; * written informed consent. Exclusion Criteria: * histological diagnosis of non-glial tumor; * patients with concomitant other solid tumors; * metastatic disease; * no surgical material/tissue available; * HIV seropositivity.
Where this trial is running
Rome
- "Regina Elena" National Cancer Institute — Rome, Italy (Recruiting)
Study contacts
- Study coordinator: Ana Belen Diaz, Doctor
- Email: anabelen.diaz@ifo.it
- Phone: 06-52662522
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.